OPEXA THERAPEUTICS

Opexa Therapeutics, Inc. (NASDAQ:OPXA) is a publicly traded biotechnology company dedicated to the development of patient-specific immunotherapies for the treatment of multiple sclerosis. The Company’s leading therapy candidate, Tcelna™, is a personalized T-cell immunotherapy in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive Multiple Sclerosis. Opexa’s mission is to lead the field of Precision Immunotherapy™ by aligning the interests of patients, employees and shareholders. Opexa is located in The Woodlands, Texas north of Houston on one acre of forested land and houses its cGMP facility, research laboratories and corporate offices.